AustralieFrV1, PascalFrancis, Curation, bibRecord, 005B75

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Identifieur interne : 005B75 ( PascalFrancis/Curation ); précédent : 005B74; suivant : 005B76

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Auteurs : J.-J. Grob [France] ; M. M. Amonkar [États-Unis] ; S. Martin-Algarra [Espagne] ; L. V. Demidov [Russie] ; V. Goodman [États-Unis] ; K. Grotzinger [États-Unis] ; P. Haney [États-Unis] ; E. K Mpgen [Allemagne] ; B. Karaszewska [Pologne] ; C. Mauch [Allemagne] ; W. H. Jr Miller [Canada] ; M. Millward [Australie] ; B. Mirakhur [États-Unis] ; P. Rutkowski [Pologne] ; V. Chiarion-Sileni [Italie] ; S. Swann [États-Unis] ; A. Hauschild [Allemagne]

Source :

Annals of oncology [ 0923-7534 ] ; 2014.

RBID : Pascal:14-0208382

Descripteurs français

Pascal (Inist)
- Homme, Perception, Protooncogène, Gène onc cellulaire, Inhibiteur, Stade avancé, Métastase, Mélanome malin, Qualité de vie, Etude comparative, Dacarbazine, Chimiothérapie, Anticancéreux, Gène BRAF, Dabrafénib.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Advanced stage, Antineoplastic agent, BRAF Gene, C-Onc gene, Chemotherapy, Comparative study, Dabrafenib, Dacarbazine, Human, Inhibitor, Malignant melanoma, Metastasis, Perception, Protooncogene, Quality of life.

Abstract

Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P<0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.

A01	`01`	`1`		`@0 0923-7534`
A03		`1`		`@0 Ann. oncol.`
A05				`@2 25`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine`
A11	`01`	`1`		`@1 GROB (J.-J.)`
A11	`02`	`1`		`@1 AMONKAR (M. M.)`
A11	`03`	`1`		`@1 MARTIN-ALGARRA (S.)`
A11	`04`	`1`		`@1 DEMIDOV (L. V.)`
A11	`05`	`1`		`@1 GOODMAN (V.)`
A11	`06`	`1`		`@1 GROTZINGER (K.)`
A11	`07`	`1`		`@1 HANEY (P.)`
A11	`08`	`1`		`@1 KÄMPGEN (E.)`
A11	`09`	`1`		`@1 KARASZEWSKA (B.)`
A11	`10`	`1`		`@1 MAUCH (C.)`
A11	`11`	`1`		`@1 MILLER (W. H. JR)`
A11	`12`	`1`		`@1 MILLWARD (M.)`
A11	`13`	`1`		`@1 MIRAKHUR (B.)`
A11	`14`	`1`		`@1 RUTKOWSKI (P.)`
A11	`15`	`1`		`@1 CHIARION-SILENI (V.)`
A11	`16`	`1`		`@1 SWANN (S.)`
A11	`17`	`1`		`@1 HAUSCHILD (A.)`
A14	`01`			`@1 Aix-Marseille University, APHM, Hôpital Timone @2 Marseille @3 FRA @Z 1 aut.`
A14	`02`			`@1 GlaxoSmithKline @2 Collegeville @3 USA @Z 2 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 13 aut. @Z 16 aut.`
A14	`03`			`@1 Department of Medical Oncology, Clínica Universidad de Navarra @2 Pamplona @3 ESP @Z 3 aut.`
A14	`04`			`@1 Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center @2 Moscow @3 RUS @Z 4 aut.`
A14	`05`			`@1 Department of Dermatology, Skin Cancer Center, University Hospital Erlangen @2 Erlangen @3 DEU @Z 8 aut.`
A14	`06`			`@1 Przychodnia Lekarska KOMED @2 Konin @3 POL @Z 9 aut.`
A14	`07`			`@1 Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne @2 Cologne @3 DEU @Z 10 aut.`
A14	`08`			`@1 Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University @2 Montreal @3 CAN @Z 11 aut.`
A14	`09`			`@1 Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia @2 Perth @3 AUS @Z 12 aut.`
A14	`10`			`@1 Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology @2 Warsaw @3 POL @Z 14 aut.`
A14	`11`			`@1 Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS @2 Padova @3 ITA @Z 15 aut.`
A14	`12`			`@1 Department of Dermatology, University Hospital Schleswig-Holstein @2 Kiel @3 DEU @Z 17 aut.`
A20				`@1 1428-1436`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22429 @5 354000501840440250`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 14-0208382`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of oncology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P<0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.
C02	`01`	`X`		`@0 002B02R`
C02	`02`	`X`		`@0 002B08A`
C02	`03`	`X`		`@0 002B04C`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Perception @5 02`
C03	`02`	`X`	`ENG`	`@0 Perception @5 02`
C03	`02`	`X`	`SPA`	`@0 Percepción @5 02`
C03	`03`	`X`	`FRE`	`@0 Protooncogène @5 03`
C03	`03`	`X`	`ENG`	`@0 Protooncogene @5 03`
C03	`03`	`X`	`SPA`	`@0 Protooncogen @5 03`
C03	`04`	`X`	`FRE`	`@0 Gène onc cellulaire @5 04`
C03	`04`	`X`	`ENG`	`@0 C-Onc gene @5 04`
C03	`04`	`X`	`SPA`	`@0 Gen onc celular @5 04`
C03	`05`	`X`	`FRE`	`@0 Inhibiteur @5 05`
C03	`05`	`X`	`ENG`	`@0 Inhibitor @5 05`
C03	`05`	`X`	`SPA`	`@0 Inhibidor @5 05`
C03	`06`	`X`	`FRE`	`@0 Stade avancé @5 06`
C03	`06`	`X`	`ENG`	`@0 Advanced stage @5 06`
C03	`06`	`X`	`SPA`	`@0 Estadio avanzado @5 06`
C03	`07`	`X`	`FRE`	`@0 Métastase @5 07`
C03	`07`	`X`	`ENG`	`@0 Metastasis @5 07`
C03	`07`	`X`	`SPA`	`@0 Metástasis @5 07`
C03	`08`	`X`	`FRE`	`@0 Mélanome malin @5 08`
C03	`08`	`X`	`ENG`	`@0 Malignant melanoma @5 08`
C03	`08`	`X`	`SPA`	`@0 Melanoma maligno @5 08`
C03	`09`	`X`	`FRE`	`@0 Qualité de vie @5 09`
C03	`09`	`X`	`ENG`	`@0 Quality of life @5 09`
C03	`09`	`X`	`SPA`	`@0 Calidad vida @5 09`
C03	`10`	`X`	`FRE`	`@0 Etude comparative @5 10`
C03	`10`	`X`	`ENG`	`@0 Comparative study @5 10`
C03	`10`	`X`	`SPA`	`@0 Estudio comparativo @5 10`
C03	`11`	`X`	`FRE`	`@0 Dacarbazine @2 NK @2 FR @5 11`
C03	`11`	`X`	`ENG`	`@0 Dacarbazine @2 NK @2 FR @5 11`
C03	`11`	`X`	`SPA`	`@0 Dacarbazina @2 NK @2 FR @5 11`
C03	`12`	`X`	`FRE`	`@0 Chimiothérapie @5 12`
C03	`12`	`X`	`ENG`	`@0 Chemotherapy @5 12`
C03	`12`	`X`	`SPA`	`@0 Quimioterapia @5 12`
C03	`13`	`X`	`FRE`	`@0 Anticancéreux @5 23`
C03	`13`	`X`	`ENG`	`@0 Antineoplastic agent @5 23`
C03	`13`	`X`	`SPA`	`@0 Anticanceroso @5 23`
C03	`14`	`X`	`FRE`	`@0 Gène BRAF @4 CD @5 96`
C03	`14`	`X`	`ENG`	`@0 BRAF Gene @4 CD @5 96`
C03	`14`	`X`	`SPA`	`@0 Gen BRAF @4 CD @5 96`
C03	`15`	`X`	`FRE`	`@0 Dabrafénib @4 CD @5 97`
C03	`15`	`X`	`ENG`	`@0 Dabrafenib @4 CD @5 97`
C03	`15`	`X`	`SPA`	`@0 Dabrafenib @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`02`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`02`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`03`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`03`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`03`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`04`	`X`	`FRE`	`@0 Agent alkylant @5 38`
C07	`04`	`X`	`ENG`	`@0 Alkylating agent @5 38`
C07	`04`	`X`	`SPA`	`@0 Agente alquilante @5 38`
N21				`@1 258`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000287

Links to Exploration step

Pascal:14-0208382

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine</title>
<author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J.-J." last="Grob">J.-J. Grob</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Aix-Marseille University, APHM, Hôpital Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M. M." last="Amonkar">M. M. Amonkar</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S." last="Martin-Algarra">S. Martin-Algarra</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Clínica Universidad de Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L. V." last="Demidov">L. V. Demidov</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V." last="Goodman">V. Goodman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K." last="Grotzinger">K. Grotzinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P." last="Haney">P. Haney</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E." last="K Mpgen">E. K Mpgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B." last="Karaszewska">B. Karaszewska</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Przychodnia Lekarska KOMED</s1>
<s2>Konin</s2>
<s3>POL</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C." last="Mauch">C. Mauch</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Miller, W H Jr" sort="Miller, W H Jr" uniqKey="Miller W" first="W. H. Jr" last="Miller">W. H. Jr Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M." last="Millward">M. Millward</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B." last="Mirakhur">B. Mirakhur</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P." last="Rutkowski">P. Rutkowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</s1>
<s2>Warsaw</s2>
<s3>POL</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V." last="Chiarion-Sileni">V. Chiarion-Sileni</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S." last="Swann">S. Swann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Dermatology, University Hospital Schleswig-Holstein</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0208382</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0208382 INIST</idno>
<idno type="RBID">Pascal:14-0208382</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000287</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005B75</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine</title>
<author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J.-J." last="Grob">J.-J. Grob</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Aix-Marseille University, APHM, Hôpital Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M. M." last="Amonkar">M. M. Amonkar</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S." last="Martin-Algarra">S. Martin-Algarra</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Clínica Universidad de Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L. V." last="Demidov">L. V. Demidov</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Russie</country>
</affiliation>
</author>
<author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V." last="Goodman">V. Goodman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K." last="Grotzinger">K. Grotzinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P." last="Haney">P. Haney</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E." last="K Mpgen">E. K Mpgen</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B." last="Karaszewska">B. Karaszewska</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Przychodnia Lekarska KOMED</s1>
<s2>Konin</s2>
<s3>POL</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C." last="Mauch">C. Mauch</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Miller, W H Jr" sort="Miller, W H Jr" uniqKey="Miller W" first="W. H. Jr" last="Miller">W. H. Jr Miller</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M." last="Millward">M. Millward</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B." last="Mirakhur">B. Mirakhur</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P." last="Rutkowski">P. Rutkowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</s1>
<s2>Warsaw</s2>
<s3>POL</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
</affiliation>
</author>
<author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V." last="Chiarion-Sileni">V. Chiarion-Sileni</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S." last="Swann">S. Swann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Dermatology, University Hospital Schleswig-Holstein</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>BRAF Gene</term>
<term>C-Onc gene</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Dabrafenib</term>
<term>Dacarbazine</term>
<term>Human</term>
<term>Inhibitor</term>
<term>Malignant melanoma</term>
<term>Metastasis</term>
<term>Perception</term>
<term>Protooncogene</term>
<term>Quality of life</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Perception</term>
<term>Protooncogène</term>
<term>Gène onc cellulaire</term>
<term>Inhibiteur</term>
<term>Stade avancé</term>
<term>Métastase</term>
<term>Mélanome malin</term>
<term>Qualité de vie</term>
<term>Etude comparative</term>
<term>Dacarbazine</term>
<term>Chimiothérapie</term>
<term>Anticancéreux</term>
<term>Gène BRAF</term>
<term>Dabrafénib</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P<0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0>
</fA01>
<fA03 i2="1"><s0>Ann. oncol.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GROB (J.-J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>AMONKAR (M. M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARTIN-ALGARRA (S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DEMIDOV (L. V.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GOODMAN (V.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GROTZINGER (K.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HANEY (P.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KÄMPGEN (E.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KARASZEWSKA (B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MAUCH (C.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MILLER (W. H. JR)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MILLWARD (M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>MIRAKHUR (B.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>RUTKOWSKI (P.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>CHIARION-SILENI (V.)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>SWANN (S.)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>HAUSCHILD (A.)</s1>
</fA11>
<fA14 i1="01"><s1>Aix-Marseille University, APHM, Hôpital Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>GlaxoSmithKline</s1>
<s2>Collegeville</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Medical Oncology, Clínica Universidad de Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Przychodnia Lekarska KOMED</s1>
<s2>Konin</s2>
<s3>POL</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne</s1>
<s2>Cologne</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</s1>
<s2>Warsaw</s2>
<s3>POL</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Dermatology, University Hospital Schleswig-Holstein</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA20><s1>1428-1436</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22429</s2>
<s5>354000501840440250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0208382</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P<0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B08A</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B04C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Perception</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Perception</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Percepción</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Protooncogène</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Protooncogene</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Protooncogen</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Gène onc cellulaire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>C-Onc gene</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Gen onc celular</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Métastase</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Metastasis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Metástasis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Mélanome malin</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Malignant melanoma</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Melanoma maligno</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Qualité de vie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Dacarbazine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dacarbazine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Dacarbazina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Gène BRAF</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>BRAF Gene</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Gen BRAF</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Dabrafénib</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Dabrafenib</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Dabrafenib</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Agent alkylant</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Alkylating agent</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Agente alquilante</s0>
<s5>38</s5>
</fC07>
<fN21><s1>258</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B75 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005B75 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0208382
   |texte=   Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri